3rd Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

About

We are pleased to invite you to the 3rd Annual Antibody Drug Conjugates Summit: From Target to Therapeutics scheduled for May 17-18, 2018 in Barcelona, Spain. This premier B2B event provides the appropriate platform to engage and discuss ideas with your fellow peers, while facilitating a professional atmosphere and environment for good company representation and development. The summit will shed light on: DISCOVERY, DEVELOPMENT & BIOANALYTICAL STRATEGIES TOWARDS NEXT GENERATION ADC: • Better understandable, more precise and new targets • Alternative scaffolds and new payloads • Optimized conjugation chemistry and stability • Improved therapeutic index SUCCESSFUL TRANSLATION INTO CLINIC & CLINICAL PROGRESS ESTABLISHING ROBUST MANUFACTURING SUPPLY CHAINS It is an honour and privilege to invite you to participate in this Summit. We look forward to welcoming you in Barcelona in May!

more info

Who Should Attend

Chief Executives, Vice Presidents, Directors, Department Heads, Leaders and Managers specialising in:

Drug Discovery
Manufacturing/CMC
Molecular Biology
Proteomics
Cell Culture
Antibody-drug conjugates (ADCs)
Immunoconjugates
Marine-based cytotoxins
Small-molecule drug conjugates
Nanoparticles / Nanobodies
PKPD
Toxicology
Assay Development
Translational Research
In Vivo
Oncology
Immunology
Biotherapeutics
Chemotherapeutics

Clinical Development
Protein Engineering
Medicinal Chemistry
Biomarkers
Antibody & Biologicsv
Bioconjugates
Monoclonal antibodies (mAbs)
Large molecule
Peptide-drug conjugates
Diabodies / Minibodies
ADME
Analytical & Formulation
Bioanalysis
In Vitro
Cancer
Haematology
Antibody-based therapeutics
Immunotherapeutics
Neurodegenerative Diseases

Speakers

Dr. Rakesh Dixit, US

Vice President, Research & Development Global Head, Biologics Safety Assessment

MedImmune

Dr. Philip Howard, UK

Chief Scientific Officer / Senior Fellow

Spirogen / MedImmune

Patrick van Berkel, UK

Senior Vice President, Research & Development

ADC Therapeutics

Dr. Madan Katragadda, US

Associate Research Fellow

Pfizer, Inc.

Dr. Magdalena Dorywalska, US

Principal Scientist, Rinat – Pfizer Oncology R&D

Pfizer, Inc.

Dr. Hans-Georg Lerchen, DE

Chief Scientist, Drug Discovery

Bayer AG

Dr. Andrea Gonzalez-Munoz, UK

Research Scientist, ADPE

MedImmune

Dr. Ling Xu, US

Principal Scientist

Mersana Therapeutics, Inc.

Dr. Laurent Ducry, CH

Head of Commercial Development for Bioconjugates

Lonza

Dr. Floris van Delft, NL

Founder & CSO, Prof. of Bioconjugate Chemistry

SynAffix / Wageningen University

Dr. Yelena Kovtun, US

Associate Director

ImmunoGen, Inc.

Dr. Sharon McGonigle, US

Senior Principal Scientist

Eisai, Inc.

Dr. Laura le Breton, FR

Analytical Scientist Bioconjugation

Novasep

Dr. Ulf Grawunder, CH

CEO

NBE-Therapeutics Ltd.

John Babcook, CA

Senior Vice President, Discovery Research

Zymeworks, Inc.

Dr. Alexander Schammel, US

Senior Scientist II in chemistry

AbbVie Stemcentrx

Dr. Frank Hanakam, DE

Director Marketing & Key Account Management

ProJect Pharmaceutics

Dr. Kai Wilkens, DE

Senior Director Sales & Marketing

Europe Advanced Cell Diagnostics, Inc.

Annual

Events

Pharma

2nd Annual Antibody Summit: Discovery, Engineering and Therapeutics

18-19

May 2017

Spain

Barcelona

Pharma

2nd Annual Antibody Drug Conjugates (ADC) Summit: From Target to Therapeutics

18-19

May 2017

Spain

Barcelona

Pharma

ADCs & Cancer Immunotherapy

25-26

February 2016

Austria

Vienna

Sponsors and Partners

Sponsor

Partner

Media partner